menu

NEWS

Tasso, Ceres Nanosciences, George Mason University, and the United States Army Medical Research Institute of Infectious Diseases receive $4.25M to develop a universal surveillance platform for infectious disease outbreaks.

MANASSAS, Va. — September 28, 2017 — Tasso, Inc. (Tasso), Ceres Nanosciences (Ceres), George Mason University (Mason), and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) today announced the commencement of a $11.7 million program, funded by the Defense Threat Reduction Agency (DTRA), to develop a reliable, safe, and simple universal surveillance platform for infectious disease outbreaks. During this multi-year program, which will be initiated with $4.25 million in funding from DTRA, Ceres will integrate its Nanotrap® particle technology, which can capture, concentrate, and preserve pathogens and other biomolecules, into Tasso’s HemoLink™ device for simple and painless collection...

READ MORE
Ceres Nanosciences and Innatoss Laboratories to Launch the Nanotrap® Lyme Antigen Test in the European Union

The Nanotrap® Lyme Antigen Test, a direct urine test for the presence of a Lyme bacteria protein, will be made available to patients throughout Europe. Ceres Nanosciences, Inc. (Ceres) and Innatoss Laboratories (Innatoss) announced today a partnership that will deliver the Nanotrap® Lyme Antigen Test out of Innatoss’ clinical testing laboratories in the Netherlands for patient benefit throughout the European Union. The Nanotrap® Lyme Antigen Test is the first highly-sensitive, urine-based test capable of directly detecting a Lyme protein antigen in a patient at any stage of infection. In 2015, Ceres launched the Nanotrap® Lyme Antigen Test for patients across...

READ MORE
Ceres Receives $750K DOD Award

Ceres receives $750K award from US Department of Defense to adapt Nanotrap® Platform to Zika and emerging febrile illness pathogens from non-invasive sample types. Ceres Nanosciences, Inc. (Ceres) today announced the commencement of a development program, funded by the Defense Advanced Research Projects Agency (DARPA) of the US Department of Defense, to use Ceres’ Nanotrap® particle technology to commercialize sample processing tools for improved detection of Zika and other emerging pathogens from non-invasively collected urine and saliva specimens. During the 12-month performance of this program, Ceres will work in collaboration with George Mason University (GMU) to adapt the Nanotrap® platform...

READ MORE
Ceres Opens $9 Million Series A Round

Ceres Nanosciences opens $9 Million Series A round with $3 Million investment from GreyBird Ventures for the development of novel diagnostics powered by its Nanotrap® Platform. Ceres Nanosciences, Inc. today announced the completion of a $3MM Million Series A financing as part of a larger, $9MM Series A round. GreyBird Ventures, an early stage venture fund, with offices in Boston, is leading the round. GreyBird is committing up to $5.5MM over the next year, and is supporting Ceres in completing the round with additional investment from strategic industry partners. The Nanotrap technology was invented at George Mason University and developed...

READ MORE
Ceres Receives $980K DOD Award

Ceres receives $980K award from US Department of Defense to adapt Nanotrap® Platform to capture immune markers from non-invasive sample types. Ceres Nanosciences to collaborate with Tufts University and George Mason University to apply Nanotrap sample processing technology to capture panel of immune system markers for detection on the Quanterix Simoa platform Ceres Nanosciences, Inc. (Ceres) today announced the commencement of a development program, funded by the Defense Advanced Research Projects Agency (DAPRA) of the US Department of Defense, to use Ceres’ Nanotrap® particle technology to assess methods of detecting panels of immune function markers in non-invasive sample types. During...

READ MORE
Atlas5D announces $3 MM Series A from GreyBird Ventures

CAMBRIDGE, MA – Atlas5D, a leader in creating solutions to help people with reduced mobility live better and richer lives, announced a $3 million Series A venture capital investment from GreyBird Ventures, LLC, a venture firm that invests in early-stage companies developing products to accelerate the nascent trend of precision medicine. Atlas5D will use the infusion of capital to continue growing its team and expanding the business. Atlas5D develops ambient sensors to precisely quantify aspects of human motion and behavior, such as speed and strength. The populations served range from very young to very old, encompass a wide variety of...

READ MORE
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER